Fundamenta Therapeutics, Ltd.
6 clinical trials · Sponsor
◉ Watch Fundamenta Therapeutics, Ltd.
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (NCT05576181) | Fundamenta Therapeutics, Ltd. | 2022-10-15 |
| Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (NCT05106907) | Fundamenta Therapeutics, Ltd. | 2021-10-25 |
| Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (NCT05106946) | Fundamenta Therapeutics, Ltd. | 2021-10-25 |
| Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies (NCT04601181) | Fundamenta Therapeutics, Ltd. | 2020-10-23 |
| Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies (NCT04384393) | Fundamenta Therapeutics, Ltd. | 2020-05-09 |
| Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies (NCT05127135) | Fundamenta Therapeutics, Ltd. | 2020-01-22 |
Track Fundamenta Therapeutics, Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.